AIM: To investigate the diagnostic accuracy of potent serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics (ROC) analysis. METHODS: We determined the serum level of apolipoprotein A-I (APO A-I), haptoglobin (HPT) and a-2 macroglobulin (A2M) with an automatic nephelometer in 63 children (age range 4-17 years, mean 10 years) with biopsy-verified chronic HBeAg-positive hepatitis B. Fibrosis stage and inflammation grade were assessed in a blinded fashion according to Batts and Ludwig. We defined mild liver fibrosis as a score < or =2 and advanced fibrosis as a score equal to 3. ROC analysis was used to calculate the power of the assays to detect advanced liver fibrosis (AccuROC, Canada). RESULTS: Serum concentrations of APO A-I, HPT and A2M were not significantly different in patients with chronic hepatitis B compared to controls. However, APO A-I level of 1.19 ng/L had a sensitivity of 85.7% and a specificity of 60.7% (AUC = 0.7117, P = 0.035) to predict advanced fibrosis. All other serum biochemical markers and their combination did not allow a useful prediction. None of these markers was a good predictor of histologic inflammation. CONCLUSION: Apolipoprotein A-I may be a suitable serum marker to predict advanced liver fibrosis in children with chronic hepatitis B.
AIM: To investigate the diagnostic accuracy of potent serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics (ROC) analysis. METHODS: We determined the serum level of apolipoprotein A-I (APO A-I), haptoglobin (HPT) and a-2 macroglobulin (A2M) with an automatic nephelometer in 63 children (age range 4-17 years, mean 10 years) with biopsy-verified chronic HBeAg-positive hepatitis B. Fibrosis stage and inflammation grade were assessed in a blinded fashion according to Batts and Ludwig. We defined mild liver fibrosis as a score < or =2 and advanced fibrosis as a score equal to 3. ROC analysis was used to calculate the power of the assays to detect advanced liver fibrosis (AccuROC, Canada). RESULTS: Serum concentrations of APO A-I, HPT and A2M were not significantly different in patients with chronic hepatitis B compared to controls. However, APO A-I level of 1.19 ng/L had a sensitivity of 85.7% and a specificity of 60.7% (AUC = 0.7117, P = 0.035) to predict advanced fibrosis. All other serum biochemical markers and their combination did not allow a useful prediction. None of these markers was a good predictor of histologic inflammation. CONCLUSION:Apolipoprotein A-I may be a suitable serum marker to predict advanced liver fibrosis in children with chronic hepatitis B.
Authors: Gabriele I Kirchner; Siegfried Wagner; Peer Flemming; Joerg S Bleck; Michael Gebel; Ingolf Schedel; Andreas Schüler; Michael Galanski; Michael P Manns Journal: Am J Gastroenterol Date: 2002-10 Impact factor: 10.864
Authors: Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: F Oberti; E Valsesia; C Pilette; M C Rousselet; P Bedossa; C Aubé; Y Gallois; H Rifflet; M Y Maïga; D Penneau-Fontbonne; P Calès Journal: Gastroenterology Date: 1997-11 Impact factor: 22.682
Authors: T Fujisawa; H Komatsu; A Inui; T Sogo; Y Miyagawa; S Fujitsuka; I Sekine; T Kosugi; M Inui Journal: J Pediatr Gastroenterol Nutr Date: 2000-02 Impact factor: 2.839
Authors: J N Rosensweig; M Omori; K Page; C J Potter; E J Perlman; S S Thorgeirsson; K B Schwarz Journal: Pediatr Res Date: 1998-09 Impact factor: 3.756
Authors: Tamara N Pereira; Peter J Lewindon; Jeffery L Smith; Therese L Murphy; Douglas J Lincoln; Ross W Shepherd; Grant A Ramm Journal: J Hepatol Date: 2004-10 Impact factor: 25.083
Authors: Dariusz Marek Lebensztejn; Maria Sobaniec-Lotowska; Maciej Kaczmarski; Irena Werpachowska; Jerzy Sienkiewicz Journal: Hepatogastroenterology Date: 2004 Jan-Feb
Authors: Laura M Keller; Stephanie Eighmy; Cun Li; Lauryn Winter; Jay Kerecman; Zachary Goodman; Naveen Mittal; Cynthia L Blanco Journal: PLoS One Date: 2020-03-09 Impact factor: 3.240